IPO Lookahead: “Leftover deals” look to come to market

This past week zero IPOs debuted, zero updated terms and one new deals were filed. Here’s a look at the up-to-date active IPO pipeline. 

With the fourth of July holiday falling on a Tuesday, the syndicate market was extremely quiet with zero IPOs coming to market and just two follow-on offerings. The upcoming week will mostly consist of past scheduled offerings which have failed to come to market. At this juncture, none of the deals on the schedule are attracting any significant street chatter. It should be noted that we will be keeping an eye out for Akcea Therapeutics (Nasdaq: AKCA) which was scheduled to come last week. This company “could” potentially adjust terms ahead of a deal in which the lead left underwriter, Cowen and Company, has stated that they will be looking to price sometime this week.

IPO Schedule – Week of 7/10

Akcea Therapeutics (Nasdaq: AKCA) is a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Co-Diagnostics, Inc. (Nasdaq: CODX) is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Moto Group (Nasdaq: MOTA) designs, manufactures and markets consumer products…including recreational and commercial drones, smart wearables and innovative mobile accessories for smartphone and camera users. The warrants have an exercise price of $12.49 per share or 125% of the common stock public offering price and expire five years from the date of issuance.

Secondary Schedule – Week of 7/10

MYnd Analytics, Inc. (Nasdaq: MYAN) is a predictive analytics company that develops decision support tools to guide personalize treatment of behavioral disorders, including depression, anxiety, bipolar disorder, and PTSD.

Reven Housing REIT (Nasdaq: RVEN) is an internally managed Maryland corporation that engages in the acquisition, ownership and operation of portfolios of leased single-family homes in the United States.